Research programme: oral heparins - DebiopharmAlternative Names: Oral heparins research programme - Debiopharm
Latest Information Update: 12 Aug 2010
At a glance
- Originator Debiopharm
- Class Heparins
- Mechanism of Action Thrombin inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Deep vein thrombosis
Most Recent Events
- 09 Mar 2005 Preclinical trials in Deep vein thrombosis in Switzerland (PO)
- 09 Mar 2005 Oral heparins is available for licensing worldwide (http://www.debio.com)